Avid Bioservices Inc
NASDAQ:CDMO

Watchlist Manager
Avid Bioservices Inc Logo
Avid Bioservices Inc
NASDAQ:CDMO
Watchlist
Price: 12.49 USD 0.08%
Market Cap: 801.1m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CDMO stock under the Base Case scenario is 15.14 USD. Compared to the current market price of 12.49 USD, Avid Bioservices Inc is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CDMO Relative Value
Base Case
15.14 USD
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.3
P/S
P/S
Price to Sales
5.3
vs History
61
vs Industry
59
Median 3Y
5.3
Median 5Y
6.5
Industry
6.9
Forward
4.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
0
Median 3Y
-4.3
Median 5Y
-4.6
Industry
22.9
Forward
-40.7
More Details
151.9
P/OCF
P/OCF
Price to OCF
151.9
vs History
4
vs Industry
1
Median 3Y
87.7
Median 5Y
59.6
Industry
19.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-13
Median 5Y
-7.1
Industry
23.5
More Details
17.8
P/B
P/B
Price to Book Value
17.8
vs History
15
vs Industry
4
Median 3Y
5.9
Median 5Y
9
Industry
2.5
More Details
6.2
EV/S
EV/S
Enterprise Value to Sales
6.2
vs History
53
vs Industry
46
Median 3Y
6.2
Median 5Y
6.5
Industry
7.4
Forward
5.6
More Details
80.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
80.2
vs History
6
vs Industry
11
Median 3Y
36.7
Median 5Y
39.9
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
3
Median 3Y
-61.2
Median 5Y
70.4
Industry
3.8
Forward
61.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
1
Median 3Y
-32.7
Median 5Y
-28.7
Industry
3.8
Forward
-96
More Details
176.1
EV/OCF
EV/OCF
Enterprise Value to OCF
176.1
vs History
4
vs Industry
1
Median 3Y
89.3
Median 5Y
58.2
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-18.1
Median 5Y
-11.8
Industry
3.5
More Details
3.3
EV/IC
EV/IC
Enterprise Value to IC
3.3
vs History
46
vs Industry
37
Median 3Y
2.9
Median 5Y
3.3
Industry
4.6
More Details

Multiples Across Competitors

CDMO Competitors Multiples
Avid Bioservices Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Avid Bioservices Inc
NASDAQ:CDMO
798.8m USD 5.3 -5.3 -94.4 -41.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 869 319.3 -165 728.7 -201 247.5 -198 951
US
Abbvie Inc
NYSE:ABBV
326.9B USD 5.7 78.6 15 22.2
US
Amgen Inc
NASDAQ:AMGN
153.3B USD 4.5 25.8 14 23.1
US
Gilead Sciences Inc
NASDAQ:GILD
137.1B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.8B USD 10.2 -114.6 24.4 25.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 020.4 -515.5 -561.4 -546.4
AU
CSL Ltd
ASX:CSL
119.6B AUD 5.1 28.1 17.3 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
54B USD 3.7 11.8 10.6 11.9
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.7 -64.3 -58
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.1B USD 16.7 -145.4 -649.3 -325.4
P/S Multiple
Revenue Growth P/S to Growth
US
Avid Bioservices Inc
NASDAQ:CDMO
Average P/S: 3 170 128.7
5.3
19%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 869 319.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 020.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.7
5%
0.7
US
S
Seagen Inc
F:SGT
19.5
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Avid Bioservices Inc
NASDAQ:CDMO
Average P/E: 33.5
Negative Multiple: -5.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 728.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.6
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.6 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.5 N/A N/A
AU
CSL Ltd
ASX:CSL
28.1
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -145.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Avid Bioservices Inc
NASDAQ:CDMO
Average EV/EBITDA: 15.2
Negative Multiple: -94.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 247.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.6
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -649.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Avid Bioservices Inc
NASDAQ:CDMO
Average EV/EBIT: 19.7
Negative Multiple: -41.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 951 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.1
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.6
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
13%
0.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -325.4 N/A N/A

See Also

Summary
CDMO intrinsic value, competitors valuation, and company profile.
DCF Valuation
CDMO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CDMO stock valuation using valuation multiples.
Wall Street Estimates
CDMO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CDMO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 258,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.